Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration

The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects

The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aciont Inc.

Adverum Biotechnologies, Inc.

Allergan Plc

Alteogen Inc.

Amakem NV

Ampio Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

Apexigen, Inc.

Applied Genetic Technologies Corporation

Benitec Biopharma Limited

Boehringer Ingelheim GmbH

Cell Medica Limited

Charlesson LLC.

Cipla Ltd.

Clanotech AB

Clearside BioMedical, Inc.

Clonz Biotech Private Limited

Coherus BioSciences, Inc.

Daiichi Sankyo Company, Limited

Diffusion Pharmaceuticals Inc.

Eleven Biotherapeutics Inc.

Exonate Limited

F. Hoffmann-La Roche Ltd.

Formycon AG

Graybug Vision Inc

GTx, Inc.

iCo Therapeutics Inc.

Icon Bioscience, Inc.

Iconic Therapeutics, Inc.

Kala Pharmaceuticals, Inc.

Kodiak Sciences Inc.

Mabion SA

MeiraGTx Limited

Mitotech S.A.

Ocular Therapeutix, Inc.

Ohr Pharmaceutical Inc.

Ophthotech Corp.

Oxford BioMedica Plc

PanOptica, Inc.

Pfenex Inc.

Pfizer Inc.

pSivida Corp.

Regeneron Pharmaceuticals Inc

RegenxBio Inc.

RXi Pharmaceuticals Corporation

Santen Pharmaceutical Co., Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

TRACON Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc.

Tyrogenex, Inc.

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Wet (Neovascular / Exudative) Macular Degeneration Overview 10

Therapeutics Development 11

Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11

Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 12

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 19

Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 25

Aciont Inc. 25

Adverum Biotechnologies, Inc. 26

Allergan Plc 27

Alteogen Inc. 28

Amakem NV 29

Ampio Pharmaceuticals, Inc. 30

Apellis Pharmaceuticals, Inc. 31

Apexigen, Inc. 32

Applied Genetic Technologies Corporation 33

Benitec Biopharma Limited 34

Boehringer Ingelheim GmbH 35

Cell Medica Limited 36

Charlesson LLC. 37

Cipla Ltd. 38

Clanotech AB 39

Clearside BioMedical, Inc. 40

Clonz Biotech Private Limited 41

Coherus BioSciences, Inc. 42

Daiichi Sankyo Company, Limited 43

Diffusion Pharmaceuticals Inc. 44

Eleven Biotherapeutics Inc. 45

Exonate Limited 46

F. Hoffmann-La Roche Ltd. 47

Formycon AG 48

Graybug Vision Inc 49

GTx, Inc. 50

iCo Therapeutics Inc. 51

Icon Bioscience, Inc. 52

Iconic Therapeutics, Inc. 53

Kala Pharmaceuticals, Inc. 54

Kodiak Sciences Inc. 55

Mabion SA 56

MeiraGTx Limited 57

Mitotech S.A. 58

Ocular Therapeutix, Inc. 59

Ohr Pharmaceutical Inc. 60

Ophthotech Corp. 61

Oxford BioMedica Plc 62

PanOptica, Inc. 63

Pfenex Inc. 64

Pfizer Inc. 65

pSivida Corp. 66

Regeneron Pharmaceuticals Inc 67

RegenxBio Inc. 68

RXi Pharmaceuticals Corporation 69

Santen Pharmaceutical Co., Ltd. 70

Sanwa Kagaku Kenkyusho Co., Ltd. 71

TRACON Pharmaceuticals, Inc. 72

TWi Pharmaceuticals, Inc. 73

Tyrogenex, Inc. 74

Xbrane Biopharma AB 75

Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment 76

Assessment by Monotherapy Products 76

Assessment by Combination Products 77

Assessment by Target 78

Assessment by Mechanism of Action 81

Assessment by Route of Administration 85

Assessment by Molecule Type 87

Drug Profiles 89

(aflibercept + nesvacumab) - Drug Profile 89

(aflibercept + rinucumab) - Drug Profile 90

A-006 - Drug Profile 91

abicipar pegol - Drug Profile 92

AC-301 - Drug Profile 95

ACX-107 - Drug Profile 96

aflibercept - Drug Profile 97

aflibercept biosimilar - Drug Profile 106

aflibercept biosimilar - Drug Profile 107

AGN-151200 - Drug Profile 108

ALG-1001 - Drug Profile 110

AMA-0428 - Drug Profile 113

APL-2 - Drug Profile 114

APX-003 - Drug Profile 116

APX-3330 - Drug Profile 117

AVA-101 - Drug Profile 119

AVA-201 - Drug Profile 122

avacincaptad pegol sodium - Drug Profile 123

axitinib - Drug Profile 125

AXT-108 - Drug Profile 127

bertilimumab - Drug Profile 128

Beta-LGND2 - Drug Profile 132

BI-144807 - Drug Profile 134

brolucizumab - Drug Profile 135

C-16Y - Drug Profile 137

CBT-128 - Drug Profile 138

CLT-005 - Drug Profile 139

CLT-28643 - Drug Profile 140

cyclosporine - Drug Profile 141

DA-3131 - Drug Profile 142

danazol - Drug Profile 143

DE-120 - Drug Profile 147

DNX-214 - Drug Profile 148

Doxarubicin Pegylated - Drug Profile 149

Drug for Age Related Macular Degeneration - Drug Profile 150

DS-7080 - Drug Profile 151

ENV-1305 - Drug Profile 152

GB-101 - Drug Profile 153

Gene Therapy 1 for Wet Age-Related Macular Degeneration - Drug Profile 154

Gene Therapy for Wet Age-related Macular Degeneration - Drug Profile 155

hI-con1 - Drug Profile 156

IVMED-50 - Drug Profile 158

IVMED-55 - Drug Profile 159

K-106 - Drug Profile 160

KSI-201 - Drug Profile 161

LHA-510 - Drug Profile 162

Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 163

OCU-200 - Drug Profile 164

OLX-301 - Drug Profile 165

ONL-1204 - Drug Profile 166

OPT-302 - Drug Profile 167

OXB-201 - Drug Profile 171

PAN-90806 - Drug Profile 173

pegpleranib sodium - Drug Profile 175

PF-05206388 - Drug Profile 178

PF-655 - Drug Profile 180

plastoquinone decyl triphenylphosphonium bromide - Drug Profile 182

Protein to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 184

ranibizumab - Drug Profile 185

ranibizumab biosimilar - Drug Profile 191

ranibizumab biosimilar - Drug Profile 192

ranibizumab biosimilar - Drug Profile 193

ranibizumab biosimilar - Drug Profile 195

ranibizumab biosimilar - Drug Profile 196

ranibizumab biosimilar - Drug Profile 197

ranibizumab biosimilar - Drug Profile 198

Recombinant Protein for Age Related Macular Degeneration - Drug Profile 199

Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration - Drug Profile 200

RES-529 - Drug Profile 201

RG-7716 - Drug Profile 205

RGX-314 - Drug Profile 206

RXI-109 - Drug Profile 208

SK-1011 - Drug Profile 214

Small Molecule for Wet AMD and Dry AMD - Drug Profile 215

Small Molecules for Dry and Wet Age Related Macular Degeneration - Drug Profile 216

Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration - Drug Profile 217

SPHINX-31 - Drug Profile 218

squalamine lactate - Drug Profile 219

sunitinib malate - Drug Profile 227

Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration - Drug Profile 229

TRC-105 - Drug Profile 230

triamcinolone acetonide - Drug Profile 238

TT-211 - Drug Profile 239

TT-231 - Drug Profile 240

X-82 - Drug Profile 241

Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects 244

Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products 248

Wet (Neovascular / Exudative) Macular Degeneration - Product Development Milestones 249

Featured News & Press Releases 249

Appendix 259

Methodology 259

Coverage 259

Secondary Research 259

Primary Research 259

Expert Panel Validation 259

Contact Us 259

Disclaimer 260

List of Tables

List of Tables

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Development by Companies, H2 2016 (Contd..3) 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Products under Development by Companies, H2 2016 26

Products under Development by Companies, H2 2016 (Contd..1) 27

Products under Development by Companies, H2 2016 (Contd..2) 28

Products under Development by Companies, H2 2016 (Contd..3) 29

Products under Development by Companies, H2 2016 (Contd..4) 30

Products under Development by Companies, H2 2016 (Contd..5) 31

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Aciont Inc., H2 2016 32

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Adverum Biotechnologies, Inc., H2 2016 33

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Allergan Plc, H2 2016 34

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Alteogen Inc., H2 2016 35

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Amakem NV, H2 2016 36

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 37

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Apellis Pharmaceuticals, Inc., H2 2016 38

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Apexigen, Inc., H2 2016 39

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Applied Genetic Technologies Corporation, H2 2016 40

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Benitec Biopharma Limited, H2 2016 41

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Boehringer Ingelheim GmbH, H2 2016 42

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Cell Medica Limited, H2 2016 43

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Charlesson LLC., H2 2016 44

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Cipla Ltd., H2 2016 45

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clanotech AB, H2 2016 46

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clearside BioMedical, Inc., H2 2016 47

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clonz Biotech Private Limited, H2 2016 48

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Coherus BioSciences, Inc., H2 2016 49

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 50

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 51

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Eleven Biotherapeutics Inc., H2 2016 52

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Exonate Limited, H2 2016 53

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 54

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Formycon AG, H2 2016 55

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Graybug Vision Inc, H2 2016 56

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by GTx, Inc., H2 2016 57

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by iCo Therapeutics Inc., H2 2016 58

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Icon Bioscience, Inc., H2 2016 59

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Iconic Therapeutics, Inc., H2 2016 60

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Kala Pharmaceuticals, Inc., H2 2016 61

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Kodiak Sciences Inc., H2 2016 62

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Mabion SA, H2 2016 63

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by MeiraGTx Limited, H2 2016 64

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Mitotech S.A., H2 2016 65

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ocular Therapeutix, Inc., H2 2016 66

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ohr Pharmaceutical Inc., H2 2016 67

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ophthotech Corp., H2 2016 68

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Oxford BioMedica Plc, H2 2016 69

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by PanOptica, Inc., H2 2016 70

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Pfenex Inc., H2 2016 71

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Pfizer Inc., H2 2016 72

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by pSivida Corp., H2 2016 73

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 74

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by RegenxBio Inc., H2 2016 75

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by RXi Pharmaceuticals Corporation, H2 2016 76

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 77

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 78

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 79

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by TWi Pharmaceuticals, Inc., H2 2016 80

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Tyrogenex, Inc., H2 2016 81

Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Xbrane Biopharma AB, H2 2016 82

Assessment by Monotherapy Products, H2 2016 83

Assessment by Combination Products, H2 2016 84

Number of Products by Stage and Target, H2 2016 86

Number of Products by Stage and Mechanism of Action, H2 2016 89

Number of Products by Stage and Route of Administration, H2 2016 93

Number of Products by Stage and Molecule Type, H2 2016 95

Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects, H2 2016 251

Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..1), H2 2016 252

Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..2), H2 2016 253

Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..3), H2 2016 254

Wet (Neovascular / Exudative) Macular Degeneration – Discontinued Products, H2 2016 255

List of Figures

List of Figures

Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 83

Number of Products by Top 10 Targets, H2 2016 85

Number of Products by Stage and Top 10 Targets, H2 2016 85

Number of Products by Top 10 Mechanism of Actions, H2 2016 88

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 88

Number of Products by Top 10 Routes of Administration, H2 2016 92

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 92

Number of Products by Top 10 Molecule Types, H2 2016 94

Number of Products by Stage and Top 10 Molecule Types, H2 2016 94

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports